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Abstract
Context—Population-level coverage for immunization against many vaccine-preventable 
diseases remains below optimal rates in the U.S. The Community Preventive Services Task Force 
recently recommended several interventions to increase vaccination coverage based on systematic 
reviews of the evaluation literature. The present study provides the economic results from those 
reviews.
Evidence acquisition—A systematic review was conducted (search period, January 1980 
through February 2012) to identify economic evaluations of 12 interventions recommended by the 
Task Force. Evidence was drawn from included studies; estimates were constructed for the 
population reach of each strategy, cost of implementation, and cost per additional vaccinated 
person because of the intervention. Analyses were conducted in 2014.
Evidence synthesis—Reminder systems, whether for clients or providers, were among the 
lowest-cost strategies to implement and the most cost effective in terms of additional people 
vaccinated. Strategies involving home visits and combination strategies in community settings 
were both costly and less cost effective. Strategies based in settings such as schools and managed 
care organizations that reached the target population achieved additional vaccinations in the 
middle range of cost effectiveness.
Conclusions—The interventions recommended by the Task Force differed in reach, cost, and 
cost effectiveness. This systematic review presents the economic information for 12 effective 
strategies to increase vaccination coverage that can guide implementers in their choice of 
interventions to fit their local needs, available resources, and budget.
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Vaccines are effective against a range of diseases and have a proven record of averting 
serious illness and death.
1,2 Based on proven effectiveness, the Advisory Committee on 
Immunization Practices has made recommendations for routine and targeted vaccinations 
since 1964, with current recommendations covering 17 vaccine-preventable diseases.
3
 The 
importance of vaccinations is further emphasized in recent economic research that indicates 




 immunization programs. Despite 
evidence of effectiveness and economic benefits, vaccination coverage (percentage of target 
population vaccinated) remains below optimum, and Healthy People 2020
6
 makes several 
recommendations for clinical and community-level interventions to increase coverage.
The present systematic economic review estimated the reach, cost to implement, and the cost 
effectiveness of 12 interventions found to be effective in increasing population-level 
coverage of appropriate vaccinations. The review was performed under the guidance of the 
Community Preventive Services Task Force (Task Force), an independent, nonfederal, 
unpaid panel of public health and prevention experts that provides evidence-based findings 
and recommendations about community preventive services, programs, and policies to 
improve health.
The first set of Task Force recommendations on vaccination intervention strategies was 
based on a Community Guide review published in 2000 (the 2000 review), covering 
evidence from papers appearing from 1980 through 1997.
7
 The present review updates the 
economic evidence from that review with studies published from January 1998 through May 
2012. An economic review of immunization information systems, published separately,
8
 is 
not included in the present review.
Evidence Acquisition
Methods developed for conducting Community Guide systematic economic reviews can be 
found at www.thecommunityguide.org/about/economics.html. A coordination team (team), 
comprising vaccination program subject matter experts from various organizations and 
systematic review experts and health economists from the Community Guide Branch at 
CDC, conducted the review with oversight from the Task Force. The team developed 
analytic frameworks, systematically searched for and identified relevant studies, and 
abstracted information from included studies. Analyses were performed in 2014.
Conceptual Approach
The 12 interventions recommended by the Task Force to increase vaccination coverage were 
conceptualized in three broad categories for both the effectiveness and economics reviews.
Interventions that enhance access to vaccination services are designed to reduce financial 
barriers (e.g., by reducing out-of-pocket costs) or reduce the inconvenience of obtaining 
vaccinations by bringing the services to clients in their homes and other non-medical 
settings. The four interventions in this category were:
• Home Visits to Increase Vaccination Rates
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• Reducing Client Out-of-Pocket Costs for Vaccinations
• Vaccination Programs in Schools and Organized Child Care Centers
• Vaccination Programs in the Special Supplemental Nutrition Program for Women, 
Infants and Children (WIC) Settings
Interventions that increase demand for vaccinations are designed to increase the number of 
people who actively seek vaccination by educating them and making them aware of their 
vaccination and risk status, by providing financial or material incentives, or by enacting 
laws. The four interventions in this category were:
• Client Reminder and Recall Systems
• Client or Family Incentive Rewards
• Vaccination Requirements for Child Care, School, and College Attendance
• Community-Based Interventions Implemented in Combination
Provider- or health system–based interventions target providers with reminders, feedback 
assessments, education, and other mechanisms designed to reduce missed opportunities to 
vaccinate receptive patients during periodic visits. The interventions in this category were:
• Provider Reminders
• Provider Assessment and Feedback
• Standing Orders
• Healthcare System-based Interventions Implemented in Combination
Detailed intervention definitions are provided in Appendix Table 1 (available online).
Inclusion Criteria
Studies were included if they:
• met the definition of one or more of the 12 interventions;
• were published in English;
• were conducted in a high-income country
9
; and
• estimated or modeled intervention cost or cost per additional person vaccinated 
(APV).
The economic concepts related to intervention outcomes in this review are described below, 
along with how the concepts are measured and constructed from variables usually reported 
in studies. The three primary outcomes of interest are reach, cost, and cost effectiveness.
Reach of intervention—The intervention’s reach is defined as the number of people in 
the target population, or, in the case of trials, in the group that received the intervention:
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Cost of intervention—The implementation and operation of vaccination programs use 
staff time, equipment, supplies, materials, facilities, utilities, and other resources. The cost of 
intervention is the cost of resources used to implement and operate it:
.
Effectiveness of intervention—The primary effectiveness of the intervention is the 
number of additional people vaccinated because of the intervention. It is the incremental 




Cost effectiveness—The primary effect of the intervention is the number of APV. Cost 
effectiveness is defined as the economic cost incurred by the intervention to achieve a unit 
increase in a health outcome. The cost effectiveness of each intervention is the intervention 
cost per APV:
.
This review focuses on the economics of strategies to increase coverage of Advisory 
Committee on Immunization Practices–recommended vaccines. The cost of vaccines is 
excluded except for the specific intervention to improve coverage through reduced patient 
out-of-pocket costs. This approach is taken to ensure that intervention costs are not unduly 
affected by differences in vaccine prices. For example, when comparing the resource use of 
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identical strategies to increase coverage of the human papillomavirus and the measles, 
mumps, and rubella vaccines, inclusion of the relevant vaccine prices will incorrectly 
indicate different resource use for implementing the same intervention strategies. However, 
it is to be noted that the uptake for different vaccines may still vary due to vaccine-specific 
attributes that are non-economic.
10
Considerable variability is expected in estimates from reviews of public health interventions. 
Hence, an important objective of Community Guide economic review methods is to try to 
explain, or at least identify, sources of variability. Estimates are converted to per person per 
year (PPPY) terms to account for intervention scale and duration. Monetary values are 
converted to a common base year in U.S. dollars to account for inflation and denomination 
in foreign currencies. All monetary values in the present review are in 2013 U.S. dollars. 
The medians and interquartile intervals are presented, where there are more than three 
estimates, so that the focus is on typical results rather than outliers when unexplained 
variation remains.
All analysis was performed in Microsoft Excel 2013.
Review Approach
The Task Force considered the evidence for each intervention and issued individual 
statements of finding for them, with no formal assessment of comparative effectiveness or 
cost effectiveness across strategies. The approach of the present review is to describe the 
results from the intervention by intervention analysis of economic data and from analysis of 
the data pooled together from all interventions to determine how reach, cost, and cost 
effectiveness varied across type of intervention and type of vaccine, as well as setting and 
baseline rate of coverage.
Types of interventions—The three primary outcomes of reach, cost, and cost 
effectiveness are postulated to vary by type of intervention. In creating the categorical 
variable for type of intervention, strategies are combined where they: were implemented in 
similar settings, targeted change in the same care behavior for providers, and targeted 
change in client behavior through financial or material incentives. Hence, strategies based in 
schools and child care settings are combined, as were provider reminders and provider 
assessments and feedback, as well as client and family incentives and reduced out-of-pocket 
costs.
Settings—Reach, cost, and cost effectiveness are expected to vary based on the setting in 
which the intervention takes place, with setting defined as the organization or social unit 
where the resources were expended. Studies that evaluated interventions related to 
vaccination requirements for school and college attendance and reduced out-of-pocket cost 
had ill-defined settings, and were excluded from the setting-based analysis.
Vaccine—Cost effectiveness drawn from different studies is postulated to vary by the types 
of vaccine(s) promoted in the interventions. These may be multiple vaccines in a series, 
multiple doses of a single vaccine, or a single dose of one or more vaccines, and the resource 
used is expected to be greater for multiple vaccines such as the childhood series than for 
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single dose vaccines such as that for influenza. Further, patients may be more receptive to 
interventions promoting certain vaccines than others, and this difference would be reflected 
in cost per APV.
Baseline coverage—Baseline rates of vaccination coverage are postulated to explain 
observed cost effectiveness, the expectation being that it would require fewer resources to 
achieve a percentage increment in coverage starting from rates that are low rather than from 
rates close to 100%. Categories of baseline rates from low to high were constructed from 
quartiles of estimates reported in the studies, with rates in the first quartile classified as low, 
those in the second and third quartiles classified as medium, and those in the fourth quartile 
classified as high.
Search Strategy and Yield
Twenty-four economic studies from the 2000 review (search period, January 1980 to 
December 1997) were included. Newer evaluation studies of the 12 intervention strategies 
were identified through a search of the literature published from January 1997 through 
February 2012. Detailed search strategy and criteria are shown in Appendix Table 2. More 
than 49,000 candidate studies were identified from the update search, of which 61 economic 
papers met the inclusion criteria (Figure 1). Hence, this review includes 84 studies: 60 
studies
11–71 (two
61,62 papers were counted as one study) from the recent search and 24 
studies
72–95 from the 2000 review.
7
Evidence Synthesis
Results for 12 Intervention Strategies Considered by the Task Force
The results from the economic reviews of the 12 recommended intervention strategies are 
summarized in Appendix Table 3, Appendix Chart 1, and Table 1. Appendix Table 3 shows 
the number of studies contributing to the economic evidence for each strategy, the period of 
study publication, the vaccines involved, and the geographic distribution across countries. 
Table 1 shows the reach of each intervention strategy, the cost to implement the strategy, and 
the cost to vaccinate an additional person using the strategy. Most studies were U.S.-based. 
The number of studies that reported both economic outcomes and effectiveness outcomes 
were almost threefold greater in the 1998–2012 period compared with 1980–1997, signaling 
the growing importance of the economic perspective in public health. Interventions to 
increase coverage of early childhood vaccines were researched most often, followed by 
influenza, hepatitis B, and pneumococcal vaccines. Many of the hepatitis B studies were 
catch-up vaccinations for adolescents and adults, especially among at-risk and new 
immigrant populations. Vaccines administered during adolescent years, such as human 
papillomavirus and meningococcal conjugate vaccine, were the least studied from the 
economic perspective. Client reminders and standing orders were among the least resource-
intensive strategies to implement and home visits and client and family incentives were 
among the most resource intensive. Strategies involving population-wide vaccination 
policies and laws and those brought to non-medical settings frequented by a target 
population had among the greatest reach. Client reminders, standing orders, and those based 
in school settings were among the most cost-effective strategies.
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Reach, Cost, and Cost Effectiveness by Intervention Strategies
Table 2 and Appendix Chart 2 present summary statistics for reach, cost per person, and cost 
per APV in nine types of intervention strategies. Requiring vaccinations for school 
attendance did not have adequate cost and cost-effectiveness data to be included in the 
analysis.
Interventions with the greatest reach, measured as the size of the intervention group, were 
those implemented in health systems such as health plans, hospitals, and health centers and 
within non-medical organizations such as schools. Cost PPPY was highest for client 
incentives and reducing client out-of-pocket costs, followed by home visits and combined 
community-based interventions. Reminder systems, whether for providers or patients, were 
least expensive to implement. Interventions that target populations in particular settings 
(e.g., schools, WIC) fell in the middle of the cost PPPY distribution. Combined interventions 
in community settings require more economic resources to implement than those in health 
systems; in the former, activities occur in dispersed community populations, whereas the 
target populations for the latter are well identified in patient panels or at the point of care.
The cost per APV followed roughly the same distribution as cost PPPY. They were among 
the highest for combinations that included home visits and manual tracking and outreach, for 
home visits alone, and for client incentives and interventions that reduce out-of-pocket cost, 
and lowest for those implementing client reminder systems and for combined interventions 
in health systems. Provider reminder and provider assessment and feedback systems are an 
exception, ranking second in terms of fewest resources to implement but fourth in highest 
cost per vaccinated person. A partial explanation may be the multiple events necessary to 
reach a successful vaccination, from provider reminder, to provider advice to client, to client 
assent.
Reach, Cost, and Cost Effectiveness by Type of Setting
Table 3 and Appendix Chart 3 provide a summary, by type of setting, of the reach, cost per 
person, and cost per vaccinated person. Some results here are repeated from the analyses 
based on type of intervention strategy because those strategies were designed and defined in 
terms of specific settings, such as in schools and in WIC offices. Combined interventions 
implemented in multiple settings appear here in the category of community. The settings of 
interventions in the included studies were clinic, community, home, hospital, MCO, 
pharmacy, school, and WIC.
The greatest reach was achieved primarily in healthcare systems such as MCOs, where 
implementers were able to access clients through membership databases, and in hospital 
settings, where implementers targeted admitted patients. Large segments of target 
populations were also reached by bringing vaccines and their administration to clients in 
non-healthcare settings such as schools and WIC offices. Cost to implement was highest 
among interventions in homes, communities, and WIC settings and lowest in MCOs and 
general practice clinics. The rank order of cost to vaccinate an additional person mirrored 
the order observed for cost to implement.
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Appendix Table 4 provides median or mean cost per vaccinated person cross-tabulated by 
type of vaccine and setting. The most prevalent types of vaccines evaluated in immunization 
programs that were also implemented in multiple settings were various childhood series, 
influenza, and hepatitis B. These are in the first three rows of the table. For the childhood 
series, the most cost effective were interventions implemented by MCOs, the least were 
those based in community settings, with those based in homes in the middle range. The cost 
per person vaccinated in influenza vaccination programs was lowest for MCOs, followed by 
clinics and schools. Vaccination programs for hepatitis B that targeted children in their 
school setting achieved additional vaccinations at much lower cost than those based in the 
community setting, where many were tailored to high-risk injection drug users.
As seen in the cost per vaccinated person based on settings, intervention strategies in the 
community setting had the highest cost per vaccinated person and those in MCOs had the 
lowest, regardless of the vaccine. Two factors that contributed to the small magnitude for 
MCOs were the large numbers of patients targeted and the interventions in operation, 
namely, client reminders by mail or phone that are less costly to implement. On the other 
hand, the studies included in the community settings category were combined interventions 
that include strategies such as home visits, client or provider education, mass media, and 
client or provider incentives that are more resource intensive to implement.
The remaining values presented in Appendix Table 4 for other vaccines are either based on 
small numbers of estimates or are isolated to a few specific settings.
Cost Effectiveness by Baseline Rate of Coverage
The median baseline rate was 44% (interquartile interval=15%, 64%) for those studies also 
reporting cost per APV. The median cost per APV was $22 for interventions occurring in 
populations with low baseline rates of coverage (≤15%), $59 for those with medium 
coverage rates (15%–64%), and $204 for those with high baseline coverage (>65%). The 
data indicate the cost to vaccinate an additional person increases with baseline coverage 
rates.
Discussion
A limitation of the present review is the search period that ended in February 2012, which 
missed more-recent research in the field. An informal search indicates there is a growing 
body of research focused on uptake of adolescent and early adult vaccines such as human 
papillomavirus and meningococcal conjugate vaccine as well as research on strategies that 
leverage the technologies of social media and electronic health records.
Because few studies evaluated the economics of strategies among rural populations, more 
research is needed to identify cost-effective strategies for rural areas. Most economic studies 
were among children, with few focusing on adolescents. The 2000 review had none, and in 
the present review only six studies focused on adolescents, primarily “catch-up” hepatitis B 
vaccinations for middle school children.
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Although reporting of costs and cost components has improved since the 2000 review,
7 
many studies still ascribe no economic value to volunteer work or in-kind contributions, 
preventing accurate estimates of societal costs. Among studies in this review, volunteers 
were common in community mobilization and community initiatives, and staff from schools 
or public health departments were used in school-based vaccination programs, sometimes to 
the detriment of their usual duties.
17
Given the relatively high cost observed for strategies using client incentives and rewards, 
further research may determine the optimal type, magnitude, and timing of incentives. 
Evidence indicates generosity is neither necessary nor sufficient for a successful program. 
Small cash gifts can motivate homeless people to return for multiple doses of hepatitis B 
vaccinations.
26,57 A program that generously distributes infant care products can fail to 
produce more vaccinations.
44
 Research on finer details is needed to optimally match the 
incentive to the target population and to design the process such that incentive receipt is 
more closely contingent on vaccination receipt.
Finally, no intervention strategy considered in this review can be effective without adequate 
vaccine supply and adequate reimbursement for the providers’ time to vaccinate. Although 
this review of evaluation studies proceeded under the assumption that all vaccines were 
readily available, the broader vaccine literature raises concerns about adequate financing to 
purchase and administer recommended vaccines,
96,97 particularly the vaccine administration 
cost of Medicaid-eligible patients in private clinics.
98,99 Issues related to financing vaccine 
purchases and administration will need to be addressed for success of interventions 
recommended by the Task Force to increase population-level coverage in real-world 
implementations.
Conclusions
This review provided estimates of reach, cost, and cost effectiveness for each of 12 
interventions recommended by the Community Preventive Services Task Force to increase 
vaccination coverage. Strategies such as reminder systems targeted to clients and providers 
showed lower cost to implement and also lower cost per APV. On the other hand, strategies 
based on home visits and combination strategies in community settings cost more to 
implement and also to vaccinate an additional person. Strategies designed to reach large 
segments of a target population, such as those based in schools and WIC settings, cost 
relatively more to implement but were able to vaccinate large numbers at a cost in the 
middle range of cost effectiveness. Schools and WIC settings may also be convenient to 
reach children who might otherwise be unvaccinated, under-immunized, or underserved.
This review does not emphasize the ranking of strategies based on cost or cost effectiveness, 
as is commonly done in league tables, because a particular strategy may be preferred based 
on other considerations for a specific population and vaccine. The results from this review 
are presented as an economic assessment of a portfolio of strategies shown to be effective in 
increasing vaccination coverage, with local decision makers expected to choose 
interventions that fit their local needs, available resources, and budget. The estimates 
provided by this review for cost per capita to implement the different interventions and 
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estimates of the likely cost to vaccinate an additional person using those interventions are 
useful information in that decision-making process.
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Definitions of Interventions to Increase Population Coverage of Appropriate Vaccinations 
Recommended by the Community Preventive Services Task Force
Intervention Definition–Description
Enhancing access to vaccination services
 Home visits to increase 
vaccination rates
Home visits intended to increase vaccination rates provide vaccinations to clients in their 
homes or promote recommended vaccinations with referral to available immunization 
services. Home visits may be conducted either by vaccination providers, such as nurses, 
or by other providers, such as social workers. Visits generally include an assessment of 
client vaccination status and a brief discussion of the importance of the indicated 
immunizations. The intervention may be directed to all clients in a designated population, 
such as low-income single mothers, or only to those clients who have been unresponsive 
to previous intervention efforts, such as client reminder and recall systems. Home visits 
may be the primary or sole intervention or one component of a larger healthcare system 
or community-based program to increase vaccination rates.
 Reducing client out-of-
pocket costs for 
vaccinations
Reducing out-of-pocket costs to families for vaccinations or administration of 
vaccinations can be implemented by paying for vaccinations or administration, providing 
insurance coverage, or reducing copayments for vaccinations at the point-of-service.
 Vaccination programs in 
schools and organized 
child care centers
Vaccination programs in schools or organized child care centers are multicomponent 
interventions delivered on-site to improve immunization rates in children and 
adolescents. These programs include two or more of the following components: (1) 
immunization education and promotion, (2) assessment and tracking of vaccination 
status, (3) referral of under-immunized school or child care center attendees to 
vaccination providers, and (4) provision of vaccinations. Additional components such as 
reduced client out-of-pocket costs, client incentives, and enhanced access to vaccination 
services may be provided. Organized child care centers include non-home day care, 
nursery or pre-school, and federal Head Start settings for children aged 5 years and 
younger. In most states, laws establishing vaccination requirements for school and child 
care center attendance require assessment, documentation, and tracking specific to each 
vaccine. Vaccination programs considered in this review either expanded the assessment 
and tracking process to other immunizations or conducted additional interventions. 
Vaccination programs are often collaborations between the school or child care center 
and local health departments, private healthcare providers, or community healthcare 
services.
 Vaccination programs in 
the Special Supplemental 
Nutrition Program for 
Women, Infants and 
Children (WIC) settings
Coordinated vaccination interventions in Special Supplemental Nutrition Program for 
Women, Infants and Children (WIC) aim to assess the immunization status of 
participating infants and children and help them get recommended vaccinations. At a 
minimum, these interventions assess each child’s immunization status and refer them to 
vaccination providers as appropriate. Additional intervention components may include 
client reminder and recall systems, manual tracking and outreach efforts, or client 
incentives to obtain recommended vaccinations (e.g., monthly voucher pickup schedules 
that require more frequent WIC visits when vaccinations are not up-to-date). In addition, 
access may be enhanced by providing vaccinations in WIC settings, or coordinating WIC 
programs with or near healthcare services.
Increasing community demand for vaccinations
 Client reminder and 
recall systems
Client reminder and recall interventions are used to remind members of a target 
population that vaccinations are due (reminders) or late (recall). Reminders and recalls 
differ in content and are delivered by various methods—telephone, letter, postcard, text 
messages, or other. Most reminder and recall systems involve a specific client, and may 
be accompanied by educational messages regarding the importance of immunization for 
the targeted vaccine.
 Client or family 
incentive rewards
Client or family incentive rewards are used to motivate people to obtain recommended 
vaccinations. Rewards may be monetary or non-monetary, and they may be given to 
clients or families in exchange for keeping an appointment, receiving a vaccination, 
returning for a vaccination series, or producing documentation of vaccination status. 
Rewards are typically small (e.g., food vouchers, gift cards, lottery prizes, baby 
products). Incentive reward programs are distinct from interventions that increase access 
to vaccination services (e.g., the provision of transportation or child care, the 
administration of vaccinations at no or reduced cost to clients).
 Vaccination 
requirements for child 
care, school, and college 
attendance
Vaccination requirements are laws or policies requiring vaccinations or other 
documentation of immunity as a condition of child care, school, and college attendance. 
Their purpose is to reduce the incidence of vaccine-preventable disease and associated 
morbidity and mortality by increasing vaccination rates. Laws are created by states, with 
the specific vaccines required established by the legislature and embodied in statutes or 
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adopted as administrative rules by health or education departments. Institutions, such as 
colleges and private schools, may establish additional vaccination policies for attendance 
or residence. Vaccination requirements vary across jurisdictions by comprehensiveness, 
acceptable documentation of immunity, access to exemptions (especially nonmedical 




Community-based interventions implemented in combination are a set of activities 
coordinated in a community to increase vaccination rates within a targeted population. 
Activities focus on increasing community demand for vaccinations and enhancing access 
to vaccination services. Efforts may also include interventions directed at vaccination 
providers. Programs are typically coordinated by a set of partnerships between 
community organizations, local government, and vaccination providers. Coordinated 
interventions may include client reminder and recall systems, the use of staff to conduct 
manual outreach and tracking of clients, mass and small media, educational activities, 
and expanded access to vaccination services.
Provider- or system-based interventions
 Provider reminders Provider reminder interventions inform those who administer vaccinations that individual 
clients are due for specific vaccinations. Techniques by which reminders are delivered 
vary, but can include notes prepared in advance and posted in client charts, alerts in 
electronic medical records, and letters sent by mail or email.
 Standing orders Standing orders authorize nurses, pharmacists, and other healthcare personnel where 
allowed by state law, to assess a client’s immunization status and administer vaccinations 
according to a protocol approved by an institution, physician, or other authorized 
practitioner. The protocol enables assessment and vaccination without the need for 
examination or direct order from the attending provider at the time of the interaction. 
Standing orders can be established for the administration of one or more specific 
vaccines to clients in health care settings such as clinics, hospitals, pharmacies, and long-
term care facilities. In settings that require attending provider signatures for all orders, 
standing order protocols permit assessment and vaccination in advance of the provider 
signature.
 Provider assessment and 
feedback
Provider assessment and feedback involves retrospectively evaluating the performance of 
providers in delivering one or more vaccinations to a client population and giving this 
information as feedback to the providers. Assessment and feedback can also involve 
other activities (e.g., incentives or benchmarking).
 Healthcare system-based 
interventions implemented 
in combination
Health care system-based interventions implemented in combination involve the use of 
two or more coordinated interventions to increase vaccination rates within a targeted 
client population. Interventions are implemented primarily in health care settings, 
although efforts may include additional activities within the community. Specific 
interventions may include client reminder and recall systems; clinic-based client 
education; expanded access in health care settings; provider assessment and feedback; 
provider reminders; and standing orders. The selection and implementation of 
coordinated interventions may result from an overall quality improvement effort in a 
health care setting.
Source: Definitions developed by the Community Guide systematic review team.
Appendix Table 2
Search for Economic Evidence - Search Strategy and Inclusion Criteria
The present review included studies that reported economic outcomes from the 2000 review1 (search period 1980–1997) 
combined with studies identified from updated searches (search period 1997–February 2012) within the standard 
medical and health-related research databases, Google Scholar, and databases specialized to economics and social 
sciences. The details of the two sets of searches are provided below.
Search Strategy
Details of the original search (1980–1997)
The following five electronic databases were searched during the original review period of 1980 up to1997: MEDLINE, 
Embase, Psychlit, CAB Health, and Sociological Abstracts. The team also reviewed reference lists in articles and 
consulted with immunization experts. To be included, a study had to:
• have a publication date of 1980–1997;
• address universally recommended adult, adolescent, or childhood vaccinations;
• be a primary study rather than, for example, a guideline or review;
• take place in an industrialized country or countries;
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• be written in English;
• meet the definition of the interventions;
• provide information on one or more outcomes related to the analytic frameworks; and
• compare a group of persons who had been exposed to the intervention with a group who had not been 
exposed or who had been less exposed. In addition, we excluded studies with least suitable designs for two 
interventions (provider reminder/recall and client reminder/recall) where the literature was most extensive.
Details of the update search (1997–February 2012)
The team conducted a broad literature search to identify studies assessing interventions to improve vaccination rates. 
The following nine databases were searched during the period of 1997 up to February 2012: CABI, CINAHL, The 
Cochrane Library, EMBASE, ERIC, MEDLINE, PSYCHINFO, Soci Abs and WOS. In addition, Google Scholar and 
specialized databases (CRD-University of York: NHS EED, EconLit, and JSTOR), were also searched. Reference lists 






To be included in the updated review, a study had to:
• have a publication date of 1997–February 2012;
• evaluate vaccinations with universal recommendations;
• meet the evidence review and Community Guide review team’s definition of the interventions;
• be a primary research study with one or more outcomes related to the analytic framework(s);
• take place in an high income country or countries;
• be written in English
• compare a group of persons who had been exposed to the intervention with a group who had not been 
exposed or who had been less exposed. In addition, we excluded studies with least suitable designs for two 
interventions (provider reminder/recall and client reminder/recall) where the literature was most extensive
Appendix Table 3
Community Preventive Services Task Force Recommended Interventions and Number of 
Included Economic Studies: Present Review and 2000 Review
Intervention Number of studies Jan 
1980 – Feb 2012 2000 
Review: Jan 1980 – Dec 
1997
By vaccine By country
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Review: Jan 1980 – Dec 
1997
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2,10 classified as home visits in the 2000 review are now reclassified as a combination strategy in the 
community.
b
There was insufficient evidence for the Task Force to determine effectiveness.
c
Two papers




 classified as a provider reminder in the 2000 review is now reclassified as a client reminder and also as a 




 classified as a combination strategy within health systems in the 2000 review is now reclassified as a 
combination strategy in the community.
Appendix Table 4
Median or Mean Cost per Vaccinated Person (Number of Estimates) by Setting and Vaccine
Clinic Community Hospital MCO Pharmacy School WIC Homes
Childhood Series $225 (15)
4,6,8,9,48,49,51,53,54,82 $1,332 (8)
4,6,10,14,65,68 $577a (1)77 $13a (3)52 — — $66 (4)33,34 $129a (3)1–3
Influenza $11 (8)
13,36,37,39,40 $69a (3)20,41,72 — $13a (2)35 $19a (1)38 $15 (6)15,18–20,22,23 — —
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— — — — — — —
DTP/OPV — $17,187a (1)
11







$184a (1)42 — $71 (5)76,79 $64a (2)43,83 — — — —
MMR $232a (1)
5
$1,590a (2)5,71 — $6a (1)45 — — — —
Tdap — — $21a (1)
78
— — — — —
Tdap/MCV/HPV $522a (1)
7
— — — — — — —
Tetanus $9 (4)
46,47 — — — — — — —




DTP, diphtheria, tetanus, pertussis; HPV, human papillomavirus; MCV, meningococcal vaccine; MMR, measles, mumps, 
rubella; Tdap, tetanus, diphtheria, pertussis; OPV, oral polio vaccine; WIC, Special Supplemental Nutrition Program for 
Women, Infants, and Children
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